Cationic Delivery Matrix for Stable Release of Antimicrobial Peptides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing delivery systems for cationic amphiphilic biologically active compounds, such as antimicrobial peptides, suffer from poor recovery and release, leading to insufficient concentrations and durations of action against infections, particularly in biofilms, due to strong binding to delivery materials and instability under physiological conditions.
Innovation Solution
A delivery system comprising a Delivery Matrix with an excess positive charge, incorporating a Cationic Component and optionally a Matrix Forming Substance, ensures efficient delivery and stability of cationic compounds like antimicrobial peptides by maintaining a positive charge density of ≥1 mEq/g, enhancing recovery and release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional delivery systems are used for cationic amphiphilic compounds, then the compounds can be delivered to the target site, but the recovery and release are poor leading to insufficient concentrations and durations of action
Solution Approach 1:
The patent changes the charge parameter of the delivery matrix from neutral or negative to positive, creating a delivery matrix with excess positive charge (≥1 mEq/g). This parameter change resolves the technical contradiction by improving recovery and release of cationic compounds through electrostatic repulsion, thereby achieving sufficient concentrations and durations of action against infections.
Solution Approach 2:
The patent employs composite materials by combining a delivery matrix with cationic compounds having excess positive charge. The delivery matrix itself may comprise cationic polymers or other cationic materials, creating a composite system where the positive charge of the matrix prevents strong binding to delivery materials, thus improving recovery and release while maintaining adequate concentration and duration of action.
2Reliability
If cationic compounds are delivered using conventional materials, then delivery can occur, but strong binding to delivery materials reduces stability and recovery
Solution Approach 1:
The patent inverts the conventional approach by using a delivery matrix with positive charge instead of neutral or negative materials. This inversion resolves the technical contradiction by using electrostatic repulsion (like charges repel) to prevent strong binding between the cationic compounds and delivery materials, thereby improving stability and reducing loss of substance through binding.
3Reliability
If high concentrations of antimicrobial peptides are used to ensure effective therapeutic doses, then infection treatment effectiveness improves, but production costs increase
Solution Approach 1:
The patent changes the charge parameter of the delivery system to positive, which improves the recovery and release of cationic antimicrobial peptides. This parameter change resolves the technical contradiction by enabling lower peptide loading concentrations while maintaining therapeutic effectiveness through improved delivery efficiency, thereby reducing production costs.
Solution Approach 2:
The positively charged delivery matrix provides self-service by utilizing its own positive charge to enhance the release and stability of cationic peptides through electrostatic repulsion. This self-service mechanism resolves the technical contradiction by eliminating the need for high peptide concentrations to achieve therapeutic doses, as the delivery system itself actively facilitates effective delivery at lower concentrations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves higher stability, recovery, and sustained release of cationic compounds, effectively preventing bacterial colonization and treating infections, including biofilms, by ensuring adequate concentrations and duration of action.
Implementation Method 1
The Delivery System combines a positively charged Delivery Matrix with a positively charged Active Component having at least one bioactive cationic compound or composition... The Delivery Matrix has an excess positive charge with a concentration (density) of positive charge which is ≥1 mEq/g of material in the Delivery Matrix
Data Source
AI summary
A Delivery System for delivery of an Active Component is provided. The Delivery System comprises a Delivery Matrix and an Active Component. The Delivery Matrix has one or both of (i) a Cationic Component; and (ii) a Matrix Forming Substance. The Cationic Component has one or both of: (i) a cationic polymer or cationic copolymer, and (ii) a positively charged non-polymeric compound or composition. The Active Component comprises a cationic bioactive. The Delivery Matrix has a mEq amount of positive charge which is equal to or exceeds the mEq amount of positive charge of the Active Component. The Delivery Matrix may comprise chitosan, or other biopolymers, synthetic polymers, matrix polymers and large molecules, which themselves are matrix forming, or are combined with a Matrix Forming Substance and one or more other Cationic Components to form the positively charged Delivery Matrix.